Baxter Pursues Haemophilia B Gene Therapy with Chatham Therapeutics Collaboration

Abstract

Baxter International has entered into an exclusive global development and commercialisation agreement with Chatham Therapeutics, an affiliate of Asklepios BioPharmaceutical, for potential treatments for haemophilia B using Chatham’s Biological Nano Particles™ gene therapy technology. Baxter has paid US$25 M upfront to advance Chatham’s haemophilia B programme through early clinical trials and has global marketing and commercialisation rights to resulting therapies.